Patents by Inventor Travis Wilson

Travis Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220194288
    Abstract: A tailgate assembly is provided for a cargo bed having a bottom wall and a front, left and right side walls. An opening is defined between the left and right side walls, and the bottom wall. The tailgate assembly includes a first panel and a second panel. The first panel is pivotally connected to the bottom wall. The first panel is pivotable between a cargo-retaining position and an unfolded position with respect to the bottom wall. In the cargo-retaining position, the first panel closes the opening. The second panel is pivotally connected to the first panel. The second panel is pivotable between a folded position and a ramp position. In the folded position, the first panel and the second panel are substantially parallel to one another and in the ramp position the first and second panels extend from one another at an angle greater than ninety degrees.
    Type: Application
    Filed: December 23, 2020
    Publication date: June 23, 2022
    Applicant: KUBOTA CORPORATION
    Inventors: Nicholas ALLICOCK, Fahmid SHARKAR, Hiroki BESSHO, Travis WILSON
  • Patent number: 11366104
    Abstract: The present technology provides methods for detecting and diagnosing diseases and conditions characterized by mitochondrial dysfunction using monocytes as an indicator of the dysfunction.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: June 21, 2022
    Assignee: STEALTH BIOTHERAPEUTICS INC.
    Inventor: D. Travis Wilson
  • Patent number: 11312993
    Abstract: The disclosure provides methods for detecting and diagnosing diseases and conditions associated with defects in cardiolipin remodeling. In some embodiments, the present technology relates to methods for detecting the presence or amount of cardiolipin isoforms and/or the presence or amount of enzymes involved in cardiolipin remodeling.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: April 26, 2022
    Assignee: STEALTH BIOTHERAPEUTICS INC.
    Inventor: D. Travis Wilson
  • Patent number: 11266709
    Abstract: The disclosure provides methods of reducing MMP-9 expression and/or MMP-9 activity in a mammalian subject. The disclosure also provides methods of increasing TIMP-1 expression and/or TIMP-1 activity in a mammalian subject. The methods comprise administering a therapeutically effective amount of an aromatic-cationic peptide to a subject in need thereof.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: March 8, 2022
    Assignee: STEALTH BIOTHERAPEUTICS INC.
    Inventors: D. Travis Wilson, Robert A. Kloner
  • Publication number: 20210401925
    Abstract: The disclosure generally describes methods of preventing or treating dominant optic atrophy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. The present technology relates generally to the treatment or prevention of Leber's hereditary optic neuropathy (LHON) or dominant optic atrophy (DOA) in mammals through administration of therapeutically effective amounts of aromatic-cationic peptides to subjects in need thereof. In one aspect, the present disclosure provides a method of treating or preventing dominant optic atrophy in a mammalian subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide.
    Type: Application
    Filed: April 16, 2021
    Publication date: December 30, 2021
    Inventor: D. Travis Wilson
  • Publication number: 20210401923
    Abstract: The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.
    Type: Application
    Filed: July 9, 2021
    Publication date: December 30, 2021
    Applicant: Stealth BioTherapeutics Corp
    Inventors: D. Travis Wilson, Mark Bamberger
  • Publication number: 20210352434
    Abstract: A contact and ranging system includes a first device that includes a first transceiver, a second transceiver, and a controller to control the first transceiver and the second transceiver of the first device. The first device is operable to determine a distance between the first device and a second device. The first transceiver is configured to perform a discovery operation. Other devices are discovered and added to a list of paired devices. A ranging schedule for each paired device in the list of paired devices is determined. The second transceiver is configured to perform a ranging operation. The ranging and response transmissions are transmitted and received by a pair of devices, such that a range between the pair of devices is determined based upon a time of flight between the pair of devices. The range between the pair of devices is matched with a timestamp and stored in a database.
    Type: Application
    Filed: May 4, 2021
    Publication date: November 11, 2021
    Inventors: Brian T. Harvey, Jason T. Grant, Travis Wilson, Nicholas Hayhoe, Warren Guthrie, Nicholas A. Schrock, John G. Videtich
  • Patent number: 11141456
    Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2?,6?-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2?,6?-Dmt-Lys-Phe-NH2.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: October 12, 2021
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Patent number: 11083771
    Abstract: The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: August 10, 2021
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventors: D. Travis Wilson, Mark Bamberger
  • Patent number: 11083772
    Abstract: The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: August 10, 2021
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventors: D. Travis Wilson, Mark Bamberger
  • Publication number: 20210220431
    Abstract: The disclosure provides methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia, and/or reducing the likelihood or severity of Friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof.
    Type: Application
    Filed: October 30, 2020
    Publication date: July 22, 2021
    Inventor: D. Travis Wilson
  • Patent number: 11021349
    Abstract: A utility vehicle having a collapsible game hanger apparatus includes a cargo box, a hitch receiver disposed under the cargo box and included in a rear structure, a hoist structure, a winch device, and a winch mounting bracket. The hoist structure consists of a base bar detachably attached to the hitch receiver, a mast attached to an end portion of the base bar, and a boom attached to an upper end of the mast. The winch device consists essentially of a winch detachably attached to a winch mounting bracket and a pulley unit for guiding the winch cable.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: June 1, 2021
    Assignee: KUBOTA CORPORATION
    Inventors: Travis Wilson, Aubrey Jarvis
  • Publication number: 20210046146
    Abstract: The invention provides methods of treating an obstructive coronary artery disease in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof and performing a coronary artery bypass graft procedure on the subject.
    Type: Application
    Filed: March 24, 2020
    Publication date: February 18, 2021
    Applicant: Stealth BioTherapeutics Corp
    Inventors: Kenneth Borow, D. Travis Wilson
  • Publication number: 20210040149
    Abstract: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.
    Type: Application
    Filed: March 13, 2020
    Publication date: February 11, 2021
    Applicant: Stealth BioTherapeutics Corp
    Inventors: D. Travis Wilson, Marc W. Andersen, Elizabeth Mead
  • Publication number: 20210038677
    Abstract: The disclosure generally describes methods of preventing or treating Lebers hereditary optic neuropathy (LHON). The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Application
    Filed: March 17, 2020
    Publication date: February 11, 2021
    Applicant: Stealth BioTherapeutics Corp
    Inventor: D. Travis Wilson
  • Publication number: 20210023160
    Abstract: This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is D-Arg-2 6-Dmt-Lys-Phe-NH2 (SS-31).
    Type: Application
    Filed: February 28, 2020
    Publication date: January 28, 2021
    Applicant: Stealth Biotherapeutics Corp
    Inventors: Kenneth Borow, D. Travis Wilson
  • Publication number: 20210025873
    Abstract: The present technology provides methods for detecting and diagnosing diseases and conditions characterized by mitochondrial dysfunction using monocytes as an indicator of the dysfunction.
    Type: Application
    Filed: April 10, 2020
    Publication date: January 28, 2021
    Applicant: Stealth BioTherapeutics Corp
    Inventor: D. Travis Wilson
  • Publication number: 20200407396
    Abstract: The disclosure provides methods of preventing, ameliorating or treating disruption of mitochondrial function and symptoms thereof. The methods provide administering aromatic-cationic peptides in effective amounts to prevent, treat or ameliorate the disruption of mitochondrial oxidative phosphorylation in a cell such as that found in a subject suffering from, or predisposed to a mitochondrial disease or disorder. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for a mitochondrial disease or disorder, an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Application
    Filed: July 15, 2020
    Publication date: December 31, 2020
    Applicant: Stealth BioTherapeutics Corp
    Inventor: D. Travis Wilson
  • Publication number: 20200397850
    Abstract: The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.
    Type: Application
    Filed: April 7, 2020
    Publication date: December 24, 2020
    Applicant: Stealth BioTherapeutics Corp
    Inventor: D. Travis Wilson
  • Publication number: 20200376074
    Abstract: The invention provides compositions and methods for preventing or treating an ischemia-reperfusion injury, such as occurs during acute myocardial infarction and organ transplant in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide or a pharmaceutically acceptable salt thereof, and one or more additional active agents such as cyclosporine.
    Type: Application
    Filed: January 14, 2020
    Publication date: December 3, 2020
    Applicant: Stealth Bio Therapeutics Corp
    Inventor: D. Travis Wilson